Anifrolumab for Lupus

(SUNFLOWER Trial)

This trial explores the effectiveness of a new treatment called anifrolumab, a type of immunotherapy, for people with lupus, a disease where the immune system attacks healthy tissue. The focus is on individuals managing lupus with antimalarial drugs but not achieving low disease activity. The study aims to determine if adding anifrolumab can help these patients reach remission and potentially reduce or eliminate the need for steroids, commonly used to control lupus. Individuals diagnosed with lupus and currently using standard treatments may consider joining this trial. As a Phase 3 trial, it represents the final step before FDA approval, offering participants a chance to contribute to the potential availability of a new treatment option.

The trial does not specify if you need to stop your current medications, but it mentions that participants must be on antimalarials with or without oral corticosteroids (OCSs). There is a tapering protocol for glucocorticosteroids (GCs), which means you might need to gradually reduce your dose if you are taking them.

Earlier research found anifrolumab generally safe for patients, with most experiencing no serious side effects. Serious issues requiring discontinuation were rare, with only three deaths reported across four studies. One study demonstrated that anifrolumab was more effective than a placebo in improving disease symptoms.

Anifrolumab is unique because it targets the type I interferon pathway, a specific immune system component that's often overactive in lupus patients. Unlike standard treatments for lupus, which typically include corticosteroids and immunosuppressants that broadly dampen the immune response, anifrolumab offers a more targeted approach, potentially reducing side effects associated with less specific therapies. Researchers are excited because this precision could lead to more effective management of lupus symptoms with fewer unwanted effects, improving overall quality of life for patients.

Research has shown that anifrolumab, the treatment under study in this trial, effectively treats lupus, particularly systemic lupus erythematosus (SLE). Studies have found that it significantly reduces disease activity and decreases the need for steroid medications. In practical use, patients experienced improvements in joint and skin symptoms without serious side effects. Many even achieved complete remission of their lupus symptoms within a few months. Overall, anifrolumab has shown promising results for people living with lupus.¹⁶⁷⁸⁹